8-K: Tonix Pharmaceuticals Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

Tonix Pharmaceuticals reports its Q4 and full year 2024 financial results, highlighting progress with TNX-102 SL for fibromyalgia and other pipeline developments.

Summary

• Tonix Pharmaceuticals announced its financial results for the fourth quarter and full year ended December 31, 2024.
• The company is preparing for the potential launch of TNX-102 SL for fibromyalgia in the fourth quarter of 2025, pending FDA approval, with a PDUFA goal date of August 15, 2025.
• Tonix expects to have sufficient cash to fund operations beyond the PDUFA goal date and the anticipated launch of TNX-102 SL.
• As of December 31, 2024, Tonix had $98.8 million in cash and cash equivalents.
• The company received positive topline results from a Phase 1 study of TNX-1500 for kidney transplant rejection and autoimmune diseases.
• Tonix also received a government grant for its potential mpox vaccine, TNX-801, which has shown single-dose immune protection in non-human primates.
• The company received first payments from a U.S. Department of Defense contract for up to $34 million over five years to develop a broad-spectrum antiviral drug program.
• Net product revenue for the fourth quarter of 2024 was approximately $2.6 million, compared to $3.8 million for the same period in 2023.
• Net product revenue for the full year 2024 was approximately $10.1 million.
• Net loss available to common stockholders was $22.1 million for the fourth quarter of 2024 and $130.0 million for the full year 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in clinical trials, FDA acceptance of the NDA for TNX-102 SL, and a strong cash position. However, the decrease in product revenue and net losses temper the overall outlook.

Positives

• The FDA accepted the NDA for TNX-102 SL for fibromyalgia, with a PDUFA goal date of August 15, 2025.
• TNX-102 SL has the potential to be the first new drug for treating fibromyalgia in more than 15 years.
• Tonix is debt-free following the repayment of a mortgage in February 2025.
• The company expects to have sufficient cash to fund operations into the first quarter of 2026.
• Positive topline results were reported from the Phase 1 study of TNX-1500.
• TNX-801 has demonstrated tolerability and immune protection against mpox in preclinical studies.
• The company received a government grant to support the development of TNX-801.
• Tonix received first payments from a DoD contract for the development of broad-spectrum antivirals.
• The company launched a national educational campaign focusing on the link between migraine, gastroparesis, and the need for non-oral acute migraine therapies.

Negatives

• Net product revenue for the fourth quarter 2024 decreased to $2.6 million from $3.8 million in the same period in 2023.
• The company reported a net loss available to common stockholders of $22.1 million for the fourth quarter 2024 and $130.0 million for the full year 2024.
• SG&A expenses for the fourth quarter 2024 increased to $15.6 million from $11.6 million in the same period in 2023.
• SG&A expenses for the full year 2024 increased to $40.1 million from $34.8 million in 2023.

Risks

• The company's product development candidates are investigational new drugs or biologics, and their efficacy and safety have not been established.
• There are risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.
• The company faces risks related to the failure to successfully market any of its products.
• There are uncertainties of patent protection and litigation.
• The company faces uncertainties of government or third-party payor reimbursement.
• The company's research and development efforts are limited, and it depends upon third parties.
• The company faces substantial competition.

Future Outlook

Tonix expects to have sufficient cash to fund planned operations into the first quarter of 2026, beyond the August 15, 2025 PDUFA goal date for TNX-102 SL. The company anticipates a potential commercial launch of TNX-102 SL in the fourth quarter of 2025, pending FDA approval. Tonix looks forward to providing additional updates on its pipeline programs in 2025.

Management Comments

• Seth Lederman, M.D., Chief Executive Officer of Tonix, stated that the company is well-positioned to launch TNX-102 SL for fibromyalgia in the fourth quarter of this year if approved by the FDA.
• Dr. Lederman believes that TNX-102 SL has the potential to be the first in a new class of non-opioid analgesic medicines for the management of fibromyalgia, and the first new drug for treating fibromyalgia in more than 15 years.
• Dr. Lederman continued, Tonix is debt free and expects to have sufficient cash to fund operations through the PDUFA target date of August 15, 2025, and the anticipated commercial launch of TNX-102 SL in the fourth quarter of this year.

Industry Context

Tonix Pharmaceuticals is focused on developing therapies for pain management and vaccines for public health challenges. The company's lead product candidate, TNX-102 SL, targets fibromyalgia, a condition affecting over 10 million adults in the U.S. The development of TNX-801 addresses the ongoing global mpox epidemic. The company's antiviral program, TNX-4200, aims to improve the medical readiness of military personnel in biological threat environments.

Comparison to Industry Standards

• Tonix's TNX-102 SL, if approved, would compete with existing fibromyalgia treatments like Lyrica (pregabalin) and Cymbalta (duloxetine), both of which are established drugs with significant market presence.
• The company's TNX-1500, an anti-CD40L monoclonal antibody, is aimed at preventing organ transplant rejection, a market dominated by immunosuppressants from companies like Novartis (Gleevec) and Roche (CellCept).
• TNX-801, the mpox vaccine candidate, would compete with Bavarian Nordic's Jynneos vaccine, which has already been approved for mpox and smallpox.
• Tonix's broad-spectrum antiviral program, TNX-4200, is targeting a market with existing antivirals like Gilead's Remdesivir, used for treating viral infections such as COVID-19.

Management Changes

Stakeholder Impact

• Shareholders may be impacted by the potential approval and commercialization of TNX-102 SL, as well as the progress of other pipeline programs.
• Employees are affected by the company's financial performance and strategic decisions.
• Patients with fibromyalgia may benefit from the potential availability of TNX-102 SL.
• The U.S. Department of Defense and military personnel may benefit from the development of broad-spectrum antivirals through the DTRA contract.
• The global community may benefit from the development of TNX-801 as a vaccine for mpox and smallpox.

Next Steps

• Continue discussions with the FDA regarding TNX-102 SL in advance of the PDUFA goal date.
• Advance TNX-1500 to a planned Phase 2 trial in kidney transplant recipients.
• Continue to advance TNX-801 vaccine for preventing mpox and smallpox towards the clinic.
• Develop a commercialization plan for TNX-801.
• Design, plan, and seek regulatory approval for a Phase I clinical study in Kenya to test the safety, tolerability, and immunogenicity of TNX-801.
• Establish physicochemical properties, pharmacokinetics, and safety attributes for TNX-4200 to support an IND submission and to fund a first-in-human Phase 1 clinical study.

Key Dates